Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
bristol-myers squibb
8
×
life sciences
national blog main
national top stories
san diego blog main
san diego top stories
san francisco blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
pfizer
abbvie
cancer
clinical trials
medicare
merck
startups
astrazeneca
cancer immunotherapy
celgene
drug prices
eli lilly
What
drug
8
×
bio
roundup
new
news
approval
approved
biotech
companies
conference
disease
liver
medical
nash
prices
race
week
adu
advanced
advantages
alnylam’s
alzheimer’s
annual
assessed
athena
attention
away
bar
beats
bff
bids
biogen
biogen’s
biopharmaceutical
bringing
brings
cancer
ceo
ceos
chief
Language
unset
Current search:
drug
×
biotech
×
" bristol-myers squibb "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push